EQ-3
According to the renowned market research company Berg Insight, eQ-3 is the European market leader in smart home for the third time in a row. The company jumps ahead with a market share of 35 percent in installed whole home solutions: About 285,000 households in Europe already use whole home solutions from eQ-3. With regard to smart thermostats, there are over 560,000 households already. In total eQ-3 has shipped more than 18 million wireless home control devices.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160802005208/en/
The market research company Berg Insight confirms the company located in Leer, Germany, as market leader in its fourth edition of the “Smart Homes and Home Automation” study. Whole home systems by eQ-3 are already installed in around 285,000 households in Europe today. These include more than six million devices based on the Homematic product line as well as the next smart home generation Homematic IP and major OEM solutions such as RWE smart home. The company has recorded continuous growth over many years in the smart home area, largely thanks to the product line Homematic introduced almost ten years ago. In the last three years, Homematic growth exceeded 75 percent per year, even with the already large installed base. According to Berg Insight, Homematic has three times more installed whole home systems in the consumer segment than all KNX manufacturers together.
The same positive trend becomes apparent when looking at the smart thermostats sector: Over 560,000 households in Europe use smart thermostats from eQ-3 already today, representing a market share of 41 percent. According to Berg Insight, the heating control system MAX! is used in 320,000 households.
In contrast to other smart thermostat solutions, eQ-3 solutions such as Homematic IP, Homematic, and MAX! provide heating control not only for the entire home, but on a room-by-room basis. Therefore, the energy is controlled based on the actual usage of rooms and associated need for heating rooms individually. This results in significantly increased energy savings. Furthermore, while other solutions typically consist of a boiler switch, a thermostat, and a gateway only, the eQ-3 solutions additionally include radiator thermostats, wall thermostats, and window sensors and other devices. When considering that a typical eQ-3 heating solution has eight to nine versus two to three devices, the European market share of eQ-3 based on the number of individual devices would be even above 70 percent.
Another major difference to other smart heating solutions is that eQ-3 provides a smooth extension path to full smart home solutions today, seamlessly adding security and alarm, light and shade, access control and many other applications for mass consumer deployment. The eQ-3 smart home products are marketed under the Homematic IP, Homematic, and MAX! brands through a wide variety of channels, including specialty retailers, Amazon and many online stores, large CE retailers, DIY, and installers that are served by our own field sales force together with the leading electrical wholesaler Sonepar. Additionally, eQ-3 is the technology and product provider behind smart home offerings from RWE, Deutsche Telekom and many other OEMs. With Homematic IP and an earlier OEM solution, eQ-3 is the pioneer in delivering an all-IPv6 smart home solution. Further strengths of Homematic IP are its ease-of-use, confirmed best-in-class security, and a leading position in data privacy thanks to a free, anonymously operated cloud service.
Homematic IP by eQ-3
About eQ-3:
eQ-3 is one of the leading innovation and technology companies for home control and consumer electronics. With more than 200 different types of products, eQ-3 today provides the largest product portfolio in the industry and has placed more than 18 million wireless solutions in more than 600,000 households on the market. This makes eQ-3 the European market leader in smart home technology based on the number of whole home solutions and electronic radiator thermostats installed. Homematic is the leading smart home platform with more than 80 devices and open communication interfaces. Homematic IP, the next generation of Homematic, is based on the Internet standard IPv6 as open platform and fully compatible with the devices of the Homematic family. The products are designed and developed at the headquarters in Leer, Germany. The final manufacturing takes place in the own production plant in South China. The ELV/eQ-3 group has been family owned since its foundation. The eQ-3 group was founded in 2007 as a spin-off from the ELV Elektronik AG, existing since 1978. Further information: www.eQ-3.de , www.HomeMatic.com , www.homematic-ip.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160802005208/en/
Contact:
Press contact:
Sinje Salamon
eQ-3 AG
Marketing
Manager
+49 (491) 6008 - 626
sinje.salamon@eq-3.de
or
PR
agency:
Benjamin Kolthoff
P.U.N.K.T. Gesellschaft
für Public
Relations mbH
+49 (40) 85 37 60 - 29
bkolthoff@punkt-pr.de
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Granted U.S. FDA Fast Track Designation for BGB-B2033 as Treatment for Hepatocellular Carcinoma18.12.2025 12:00:00 CET | Press release
BGB-B2033 is a bispecific antibody directed at GPC3 and 4-1BB; key targets in the most common liver cancerFDA Fast Track Designation reflects the potential of BGB-B2033 in an area of high unmet need BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company Fast Track Designation for BGB-B2033, its GPC3x4-1BB bispecific antibody for the treatment of adult patients with hepatocellular carcinoma (HCC) with disease progression on or after prior systemic treatment. “The FDA awards Fast Track Designation to therapies that show potential to address an unmet medical need in serious or life-threatening conditions. The FDA’s decision reflects the encouraging profile of BGB-B2033 in advanced hepatocellular carcinoma, where patients continue to face limited treatment options,” said Julie Lepin, Senior Vice President and Chief Regulatory Affairs Officer at BeOne. BeOne is currentl
NHOA Energy Achieves Great Place To Work Certification in Italy, the United States and Australia18.12.2025 10:53:00 CET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, announces that it has been certified Great Place To Work® in Italy, the United States, and Australia. The certification is based entirely on direct feedback from NHOA Energy employees, gathered through an independent and structured listening process. Great Place To Work® Certification™ assesses the quality of the employee experience across key dimensions such as credibility, respect, fairness, pride, and camaraderie. The results achieved by NHOA Energy reflect a corporate culture built on trust, inclusion, and the consistent commitment to valuing people within a dynamic and international environment. Employees highlighted particularly high levels of appreciation for the ethical and transparent behavior of leaders, the welcoming and inclusive approach toward new hires, and fair treatment across diversity, equity, and inclusion dimensions. A strong majority also expressed pride in working at NHOA Energy and reported a
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 10:00:00 CET | Press release
The deal further strengthens Regnology’s global position in Regulatory Reporting and significantly accelerates its expansion into new markets Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeki
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 10:00:00 CET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press release
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated with zasocitinib achieved clear or almost clear skin (PASI 90), and on average about 30 percent achieved completely clear skin (PASI 100) by week 16 Zasocitinib was generally well-tolerated with a safety profile consistent with previous clinical studies Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at wee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom